IXICO plc - IXICO announces client contracts and appointed CBO
28 October 2019
("IXICO" or the "Company")
IXICO announces client contracts and appointment of Chief Business Officer
The new contracts are:
· A start up agreement with a new client for a new multi-study programme in Progressive Supranuclear Palsy (PSP), with an initial value of c£0.4 million, over 12 months
· A c£0.35 million, three-year, expansion of an existing study to add a significant patient cohort in
· A c£0.45 million, two-year, new client contract to support a Phase IV study for a US biotech client, exploring a new application for a marketed drug for mental health
The Company has been contracted to initiate work on a new PSP programme for a client, ahead of patient enrolment later in 2019. The first study in the programme has a value of approximately
An existing client has also initiated a new requirement to enrol patients in
A new US-based biotechnology client has contracted IXICO to provide imaging analytics services to support a Phase IV programme in mental health. The study will validate an additional indication for an established therapy, enabling more patients to benefit.
The Company has also appointed
"Following an exceptionally strong close in FY19, we are pleased to keep up this momentum with new contracts and new commercial leadership talent coming on board. This demonstrates the adaptability of IXICO's core technology and ability to unlock insights on a broad range of neurological disorders and across the full spectrum of clinical development. We are also delighted to announce Lammert's appointment as Chief Business Officer. He brings deep knowledge of the global CNS clinical trials market and a strong track record of delivering revenue growth. His experience will further support our strategy of growth through international expansion."
For further information please contact:
| || |
+44 (0) 20 3763 7498
| || |
Cenkos Securities PLC (Nominated adviser and sole broker)
+44 (0) 20 7397 8900
| || |
Michael F Johnson /
| || |
+44 (0) 203 950 9144
Mary Clark /
IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease.
Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare disease, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the
Quick facts: IXICO PLC
Market Cap: £31.08 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE